Establishing Patient Registries for Rare Diseases: Rationale and Challenges
Tóm tắt
Từ khóa
Tài liệu tham khảo
Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Lipkin G, Calvert M. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.
Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16–23.
GARD. FAQS about rare diseases. 2017. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rarediseases. Accessed 20 Feb 2020.
Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Groups. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–14.
Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196.
Gavin P. The importance of natural histories for rare diseases. Expert Opinion Orphan Drugs. 2015;3:355–7.
Kodra Y, de la Paz MP, Coi A, Santoro M, Bianchi F, Ahmed F, Rubinstein YR, Weinbach J, Taruscio D. Data quality in rare diseases registries. Adv Exp Med Biol. 2017;1031:149–64.
Maccarthy J, Guerin S, Wilson AG, Dorris ER. Facilitating public and patient involvement in basic and preclinical health research. PLoS One. 2019;14(5):e0216600.
Fink AK, Loeffler DR, Marshall BC, Gross CH, Morgan WJ. Data that empower: the success and promise of CF patient registries. Pediatr Pulm. 2017;52:544–51.
Gliklich R, Dreyer N, Leavy M. Registries for evaluating patient outcomes: a user’s guide. Agency for Healthcare Research and Quality. 2014. https://www.ncbi.nlm.nih.gov/books/NBK208616/. Accessed 20 Feb 2020.
U.S. Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. 2018. https://www.fda.gov/media/120060/download. Accessed 20 Feb 2020.
Martins AM, Obikawa SK. The importance of patient registries for rare diseases. Expert Opinion Orphan Drugs. 2013;1:769–72.
D’Agnolo HM, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JP. Creating an effective clinical registry for rare diseases. United Eur Gastroenterol J. 2016;4(3):333–8.
Tabor HK, Goldenberg A. What precision medicine can learn from rare genetic disease research and translation. AMA J Ethics. 2018;20(9):834–40.
US National Library of Medicine. What is precision medicine? 2019. https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Accessed 20 Feb 2020.
US Food and Drug Administration. Rare diseases: natural history studies for drug development guidance for industry. 2019. https://www.fda.gov/media/122425/download. Accessed 20 Feb 2020.
The Office of the National Coordinator for Health Information Technology. Strategic Plan. 2020. https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf. Accessed 20 Feb 2020.
Congress. Public Law 114–255. 2016. https://www.govinfo.gov/content/pkg/PLAW-114publ255/pdf/PLAW-114publ255.pdf. Accessed 20 Feb 2020.
Wilkinson MD, Dumontier M, Aalbersberg I. The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016. https://doi.org/10.1038/sdata.2016.18.
Wise J, de Barron AG, Splendiani A, Balali-Mood B, Vasant D, Little E, Mellino G, Harrow I, Smith I, Taubert J, van Bochove K, Romacker M, Walgemoed P, Jimenez RC, Winnenburg R, Plasterer T, Gupta V, Hedley V. Implementation and relevance of FAIR data principles in biopharmaceutical R&D. Drug Discov Today. 2019;24(4):933–8.
Comet Initiative. Core outcome measures in effectiveness trials. http://www.comet-initiative.org/. Accessed 20 Feb 2020
COSMIN. About the COSMIN initiative. https://www.cosmin.nl/about/. Accessed 20 Feb 2020.
US Food and Drug Administration. Accelerated Approval. 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval. Accessed 20 Feb 2020.
Chawla NV, Davis DA. Bringing big data to personalized healthcare: a patient-centered framework. J Gen Intern Med. 2013;28(3):660–5.
O’Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood). 2004;Suppl Variation:63–72.
Ieva F, Gale CP, Sharples LD. Contemporary roles of registries in clinical cardiology: when do we need randomized trials? Expert Rev Cardiovasc Ther. 2014;12(12):1383–6.
US Food and Drug Administration. Patient Listening Sessions. 2020. https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-listening-sessions. Accessed 20 Feb 2020.
US Food and Drug Administration. FDA-led patient-focused drug development (PFDD) public meetings. 2020. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/fda-led-patient-focused-drug-development-pfdd-public-meetings. Accessed 20 Feb 2020.
US Food and Drug Administration. Externally-led patient-focused drug development meetings. 2019. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/externally-led-patient-focused-drug-development-meetings. Accessed 20 Feb 2020.
Flood J, Minkler M, Hennessey LS, Estrada J, Falbe J. The collective impact model and its potential for health promotion: overview and case study of a healthy retail initiative in San Francisco. Health Educ Behav. 2015;42(5):654–68.
National Organization for Rare Disorders. Five years of patient registry success: NORD’s IAMRARE™ registry program celebrates new partnerships and models of engagement. 2018. https://rarediseases.org/five-years-of-patient-registry-success-nord-iamrare-registry-program-celebrates-new-partnerships-models-engagement/. Accessed 20 Feb 2020.
Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6.
ALS News. NIH Rare Disease Day highlights joint networks advancing array of research. 2019. https://alsnewstoday.com/2019/03/05/nih-rare-disease-day-highlights-joint-networks-advancing-array-of-research/. Accessed 20 Feb 2020.
Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y, Bushby K. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis. 2016. https://doi.org/10.1186/s13023-016-0398-y.
Bellgard M, Beroud C, Parkinson K, Harris T, Ayme S, Baynam G, Weeramanthri T, Dawkins H, Hunter A. Dispelling myths about rare disease registry system development. Source Code Biol Med. 2013. https://doi.org/10.1186/1751-0473-8-21.
Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50.
Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619–25.
The United Nations. Declaration on Universal Health Coverage. 2019. https://undocs.org/en/A/RES/74/2. Accessed 20 Feb 2020.
Critical Path Institute. Funded by FDA, C-Path and NORD to launch rare disease data and analytics platform. 2019. https://c-path.org/c-path-and-nord-to-launch-fda-funded-rare-disease-data-analytics-platform/. Accessed 20 Feb 2020.